What happens after you stop retatrutide?

If you are taking or considering retatrutide, it is fair to ask what happens when you stop. The honest starting point is that retatrutide is still investigational. Its published evidence is a Phase 2 obesity trial in which the top dose produced a mean 24.2% body-weight reduction at 48 weeks^[3], and no published trial has yet followed people after they came off it. To answer the question, we look at the closest evidence available: the withdrawal trials for the two approved drugs in the same family, semaglutide and tirzepatide. In both, stopping the drug reversed most of the weight that had been lost.

Retatrutide has no discontinuation trial of its own

Retatrutide activates three receptors at once: GLP-1 (a gut hormone that reduces appetite), GIP (a second gut hormone that supports insulin release), and glucagon (a hormone that raises energy expenditure). That triple design is why its Phase 2 numbers ran higher than the earlier drugs, with 24.2% mean weight loss on the 12 mg dose against 2.1% on placebo in 338 adults^[3]. But every retatrutide trial published so far has measured what the drug does while people take it, not what happens after they stop. There is no randomised withdrawal readout for retatrutide, so anyone claiming to know exactly how you will respond after stopping is guessing. The useful evidence sits one step over, in the drugs that reached the market first.

What happened when people stopped semaglutide

STEP-4 is the cleanest test for semaglutide. Participants took the drug for 20 weeks, then half were switched to placebo and half kept going. Those who kept taking semaglutide lost a further 7.9% of body weight from week 20 to week 68. Those switched to placebo gained 6.9% back over the same period, a gap of 14.8 percentage points^[1]. The people who stopped did not climb all the way back to their starting weight, but they gave back most of what the drug had delivered.

What happened when people stopped tirzepatide

SURMOUNT-4 asked the same question of tirzepatide. After a 36-week lead-in, participants had lost a mean 20.9% of body weight. They were then randomised to continue tirzepatide or switch to placebo. Over the following year the continuation group lost an additional 5.5%, while the placebo group regained 14.0%, a difference of 19.4 percentage points^[2]. The trial authors put it plainly: withdrawing the drug led to substantial regain, and continued treatment held the loss in place.

Why the weight comes back

None of this is a failure of the drugs. It is how they work. GLP-1 based medicines lower appetite and slow the stomach while the drug is in the body. Take the drug away and those signals fade, hunger tends to return, and for most people the weight follows. Obesity behaves like a chronic condition in this respect, closer to high blood pressure than to a course of antibiotics: the treatment manages the problem rather than curing it. Retatrutide adds a glucagon component the older drugs do not have, and whether that changes the regain curve one way or the other is genuinely unknown, because the trial that would answer it has not been run.

The two withdrawal trials also show that regain is gradual rather than instant. In STEP-4 the switch to placebo happened at week 20 and weight climbed back through week 68. In SURMOUNT-4 the switch happened at week 36 and the regain accumulated over the year that followed. Appetite and weight return over months, not overnight, which is part of why the effect can be easy to underestimate at the moment of stopping. The same pattern is what any reader of the tirzepatide and semaglutide coverage should carry over to retatrutide until its own data arrives.

What this means if you are thinking about retatrutide

Two practical points. First, there is no lawful, approved route to retatrutide today outside a clinical trial, and the grey-market vials sold online are not the trial product and have not been assessed by any regulator for identity, purity, or safety. Second, if the approved drugs are any guide, the benefit of a GLP-1 based medicine lasts as long as treatment does, so stopping is a decision to plan for rather than to improvise. That planning belongs with a clinician who knows your history, not a forum thread or a vendor's dosing sheet.

The medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Retatrutide is an investigational compound with no regulatory approval anywhere in the world as of this writing. Peptides discussed here may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before starting or stopping any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product. For the country-by-country position, see the retatrutide regulation pages.